A recent public discussion around the UK Biobank, following reports of attempted misuse of anonymised research data, has once again placed biobanking in the spotlight. While the incident understandably raised questions about security and privacy, it also highlighted something equally important: just how essential biobanks have become for medical progress.
Every major advance in neuroscience begins with a better understanding of disease. That understanding often depends on something very concrete: carefully collected biological material, linked to high-quality clinical information and preserved over time. Biobanks make that possible.
A long-term investment in knowledge
Research into neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, or ALS rarely advances through a single breakthrough. Progress comes step by step, often over decades.
Samples collected many years ago can suddenly gain new value when technologies evolve. Cerebrospinal fluid stored in a freezer fifteen years ago may today help identify biomarkers that did not yet exist at the time of collection. Brain tissue preserved after donation may later support entirely new research questions. Biobanking is therefore not simply storage. It is long-term stewardship.
At IBB, every sample is collected, processed, documented, and preserved according to strict scientific, ethical, and legal frameworks. This takes considerable expertise, time, and resources, but it creates something invaluable: a scientific infrastructure that allows future discoveries to happen.
Sharing responsibly
Biobanking only works if material can ultimately be used. At the same time, public trust is essential. Samples and associated data must be handled securely, ethically, and transparently. Researchers should have access where scientifically justified, while privacy and governance remain safeguarded.
In our view, the answer to occasional misuse or concern is not to isolate valuable scientific resources behind ever higher walls. Rather, it is to continue improving oversight, transparency, and responsible governance.
A societal choice
Biobanks are expensive to build and maintain. They require infrastructure, specialist staff, governance systems, and long-term public commitment.
But their return on investment is equally long-term: better diagnostics, earlier detection, new biomarkers, more targeted treatments, better understanding of disease… The benefits are scientific, but also societal and economic.
For IBB, biobanking is ultimately an act of solidarity between generations: material donated today may help answer questions that future patients, families, and researchers have not even asked yet. The challenge is not only to preserve valuable material, but to ensure that it can continue to serve science safely, ethically, and meaningfully.
